No Data
No Data
Retail Investors Among Daan Gene Co., Ltd.'s (SZSE:002030) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 6.3% Last Week
Daan Gene Co., Ltd. (002030.SZ): The company is currently not involved in any AI pharmaceutical projects.
On July 26th, Gelonghui reported that Daan Gene Co., Ltd. (002030.SZ) stated on the investor interaction platform that the company is not currently involved in AI pharmaceutical projects.
Daan Gene Co.,Ltd.: 2024 Interim Performance Forecast
Daan Gene Co., Ltd (002030.SZ) is expected to suffer a loss of 0.35 billion to 0.43 billion yuan in the first half of the year.
On July 10th, Gelunhui reported that Daan Gene Co., Ltd. (002030.SZ) is expected to lose between 350 million and 430 million yuan in the first half of the year, with a non-net loss of 130 million to 180 million yuan. (1) During the reporting period, due to a decrease in market demand and adjustment of centralized procurement prices, the company's revenue decreased, and net income attributable to shareholders of the listed company decreased from the same period last year. (2) During the reporting period, due to the fair value changes of the company's other non-current financial assets, the impact on net income attributable to shareholders of the listed company was approximately -250 million yuan, which is part of non-recurring gains and losses.
Daan Gene Co., Ltd. (002030.SZ): As of June 28th, the total number of shareholders in the company is approximately 1,503,000.
Daan Gene Co., Ltd. (002030.SZ) stated on the investor interaction platform on July 8th that as of June 28, 2024, the total number of shareholders in the company was approximately 1.53 million households.
daan gene co.,ltd. (002030.SZ): Its subsidiary has obtained the medical instruments registration certificate for hepatitis C virus antibody (HCV) control product.
On June 24, Gelonhui reported that Daan Gene Co., Ltd. (002030.SZ) announced that its subsidiary, Guangzhou Darui Biotechnology Co., Ltd., has recently obtained a medical device registration certificate issued by the National Medical Products Administration of China for the Hepatitis C Virus Antibody (HCV) Reference Material. The certificate number is National Machinery Standard 20243401117. The validity period is from the date of approval to June 17, 2029. The expected use is for the critical value correction of the qualitative test of the Hepatitis C Virus Antibody. Currently, the company's subsidiary, Guangzhou Darui Biotechnology Co., Ltd., is the majority shareholder.
No Data